Capricor Therapeutics Q3 2026 earnings
Operating loss widened to $42.7M in Q3 2026 as R&D and G&A expenses increased, while cash and investments declined to $198.5M.
Headline numbers
| Metric | Actual | YoY | QoQ | 8-K location |
|---|---|---|---|---|
| Revenue | $— | — | — | Ex. 99.1, income statement |
| EPS (GAAP) | -$0.73 | -0.19 | — | Ex. 99.1, income statement |
| Net income | -$42,656,101 | -$18,085,554 | — | Ex. 99.1, income statement |
| Adj. EBITDA | -$42,656,101 | -$24,570,647 | — | Ex. 99.1, income statement |
| Adj. EBITDA margin | -100% | -100% | — | Ex. 99.1, income statement |
Revenue breakdown
not stated in the 8-K
Margins and costs
- Gross margin not stated in the 8-K
- Operating expenses $44.7M (+69.8% YoY)
- One-offs in the quarter not stated in the 8-K
- Effective tax rate not stated in the 8-K
- Non-GAAP bridge No non-GAAP reconciliation provided; GAAP loss equals Adj. EBITDA loss.
KPIs
| Metric | Actual | Prior quarter | Prior year | Change |
|---|---|---|---|---|
| Cash, cash equivalents, restricted cash and marketable securities | $198.5M | $237.9M | $318.1M | -$39.4M QoQ, -$119.6M YoY |
| Research and development | $29.6M | $28.9M | $20.4M | +$0.7M QoQ, +$9.2M YoY |
| General and administrative | $15.1M | $14.1M | $5.9M | +$1.0M QoQ, +$9.2M YoY |
Guidance
not stated in the 8-K
What drove it
- Revenue story No revenue reported in Q3 2026.
- EPS story GAAP loss per share widened to -$0.73 from -$0.54 in Q3 2025, driven by increased operating expenses.
- One-off check No one-off items identified in the income statement.
The good
- Investment income of $2.0M in Q3 2026, up from $1.7M in Q3 2025.
The bad
- Operating loss increased to $42.7M in Q3 2026 from $27.7M in Q3 2025.
- Cash and investments declined to $198.5M from $237.9M in Q2 2026.
The ugly
- none
Open questions
- The release does not disclose the specific amount of the investment income or the nature of the unrealized gains/losses on marketable securities.
- The release does not provide a reconciliation of the GAAP loss to a non-GAAP measure.
Full release
Capricor Therapeutics (CAPR) earnings release, November 10, 2026
Capricor Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
SAN DIEGO, Nov. 10, 2026 (GLOBE NEWSWIRE) — Capricor Therapeutics
(NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced its financial results for the third quarter ended September 30, 2026, and provided a corporate update.
“This quarter, we took important steps forward on both our regulatory filing and our launch readiness, submitting two-year HOPE-3 OLE data in a major amendment to our BLA while advancing our manufacturing and commercial preparations. In the OLE phase, patients who switched from placebo to Deramiocel saw their upper limb decline slow by 76% compared with their year on placebo, and this past weekend our HOPE-3 cardiac results received the AHA Outstanding Research Award in Pediatric Cardiology. As Duchenne progresses, boys and young men lose the use of their arms and hands, and with it their independence, which is what Deramiocel is designed to slow. We appreciate the FDA’s engagement throughout this review and are encouraged by the Agency’s current focus on rare disease, including its recently launched Rare Disease Framework Initiative. As we approach our PDUFA date, we remain confident in the strength of our data. With our San Diego facility operational, we are prepared to move quickly to bring Deramiocel to patients, if approved,” said Linda Marbán, Ph.D., Capricor’s Chief Executive Officer.
Third Quarter 2026 and Recent Highlights
Third Quarter 2026 Financial Results
Upcoming Investor Events
Information on upcoming investor events will be available on the Investors section of Capricor’s website.
Conference Call and Webcast
To participate in the conference call, please dial 1-800-717-1738 (Domestic) or 1-646-307-1865 (International) and reference the conference ID: 13662. Participants may dial in using the numbers above and ask to be joined to the call or click the
Call Me™ link for instant telephone access to the event. To participate via a webcast, please click here. A replay of the webcast will be available shortly after the conclusion of the live event and will be accessible in the Investors section of the Company’s website.
About Duchenne Muscular Dystrophy
Duchenne muscular dystrophy (DMD) is a severe, X-linked genetic disorder characterized by progressive muscle degeneration affecting the skeletal, respiratory, and cardiac muscles. It is caused by the absence of functional dystrophin, a key structural protein in muscle cells. DMD affects approximately 15,000 individuals in the United States, primarily males. Over time, deterioration of the heart muscle leads to cardiomyopathy and heart failure, the leading cause of death in DMD. There is no cure, and treatment options remain limited.
About Deramiocel
Deramiocel (CAP-1002) consists of allogeneic cardiosphere-derived cells (CDCs), a rare population of cardiac cells that have been shown in preclinical and clinical studies to exert immunomodulatory and anti-fibrotic actions in the preservation of skeletal and cardiac muscle function in muscular dystrophies such as DMD. CDCs act by secreting extracellular vesicles known as exosomes, which target macrophages and alter their expression profile to adopt a healing rather than pro-inflammatory phenotype. For the treatment of DMD, Deramiocel holds Orphan Drug, RMAT and Rare Pediatric Disease designations in the U.S., and Orphan Drug and ATMP designations in Europe. The Rare Pediatric Disease designation may qualify Capricor for a Priority Review Voucher upon approval.
About Capricor Therapeutics
Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing cell and exosome-based therapeutics for the treatment of rare diseases. Our lead product candidate, Deramiocel, is an allogeneic cardiac-derived cell therapy in late-stage development for the treatment of Duchenne muscular dystrophy, evaluated in clinical studies for its potential to preserve skeletal and cardiac muscle function. Capricor is also advancing its proprietary StealthX™ exosome platform for the targeted delivery of oligonucleotides, proteins, and small-molecule therapeutics across a range of diseases. At Capricor, we are committed to delivering new therapies for patients with rare diseases. For more information, visit capricor.com, and follow Capricor on
Facebook,
Instagram and
X.
Financial statements
Income Statement
Three Months Ended September 30, — (UNAUDITED)
| Three Months Ended September 30, – 2026 | Three Months Ended September 30, – 2025 | Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 | |
|---|---|---|---|---|
| REVENUE | ||||
| Revenue | $— | $— | $— | $— |
| OPERATING EXPENSES | ||||
| Research and development | 29,558,388 | 20,359,098 | 85,801,592 | 61,321,924 |
| General and administrative | 15,124,348 | 5,924,942 | 38,599,617 | 17,662,598 |
| TOTAL OPERATING EXPENSES | 44,682,736 | 26,284,040 | 124,401,209 | 78,984,522 |
| LOSS FROM OPERATIONS | -44,682,736 | -26,284,040 | -124,401,209 | -78,984,522 |
| OTHER INCOME (EXPENSE) | ||||
| Other income | 749 | -106 | -69,978 | -123,303 |
| Investment income | 2,025,886 | 1,713,499 | 7,141,687 | 4,236,393 |
| TOTAL OTHER INCOME (EXPENSE) | 2,026,635 | 1,713,393 | 7,071,709 | 4,113,090 |
| LOSS BEFORE INCOME TAXES | -42,656,101 | -24,570,647 | -117,329,500 | -74,871,432 |
| (Provision for) benefit from income taxes | -1,600 | -1,600 | ||
| NET LOSS | -42,656,101 | -24,570,647 | -117,331,100 | -74,873,032 |
| OTHER COMPREHENSIVE INCOME (LOSS) | ||||
| Net unrealized gain (loss) on marketable securities | 9,648 | -543,452 | -437,047 | -182,833 |
| COMPREHENSIVE LOSS | -42,646,453 | -25,114,099 | -117,768,147 | -75,055,865 |
| Net loss per share, basic and diluted | -0.73 | -0.54 | -2.03 | -1.64 |
| Weighted average number of shares, basic and diluted | 58,128,772 | 45,716,151 | 57,832,339 | 45,687,630 |
Balance Sheet
September 30, 2026 — SUMMARY BALANCE SHEETS
| September 30, 2026 – (unaudited) | December 31, 2025 | |
|---|---|---|
| Cash, cash equivalents, restricted cash and marketable securities | 198,538,594 | 318,128,915 |
| Total assets | 330,370,421 | 355,949,294 |
| Total liabilities | 120,605,812 | 50,157,149 |
| Total stockholders’ equity - 58,138,989 and 57,370,909 common shares issued | ||
| and outstanding at September 30, 2026 and December 31, 2025, respectively | 209,764,609 | 305,792,145 |
| Total liabilities and stockholders’ equity | 330,370,421 | 355,949,294 |
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor’s product candidates; the initiation, conduct, size, timing and results of clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including future interactions with regulatory authorities and the ability to obtain regulatory approvals or otherwise bring products to market; manufacturing capabilities; dates for regulatory meetings; the potential that required regulatory inspections may be delayed or not be successful, which would delay or prevent product approval; revenue and reimbursement estimates; projected terms of definitive agreements, our financial position, our possible uses of existing cash and investment resources; results of securities litigation; and statements regarding our litigation with Nippon Shinyaku Co., Ltd. and NS Pharma, Inc., including the nature of the dispute, our expectations regarding any legal proceedings, and our ability to commercialize Deramiocel independent of our existing distribution agreement; and any other statements about Capricor’s management team’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “could,” “anticipates,” “expects,” “estimates,” “should,” “target,” “will,” “would” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor’s business is set forth in Capricor’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the Securities and Exchange Commission on March 17, 2026, and in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, as filed with the Securities and Exchange Commission on August 14, 2026. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.
Deramiocel and Capricor’s StealthX™ exosome therapeutics are investigational and have not been approved for commercial use in any indication.
For more information, please contact:
Capricor Media Contact:
Caitlin Kasunich / Raquel Cona
KCSA Strategic Communications ckasunich@kcsa.com / rcona@kcsa.com
212.896.1241 / 516.779.2630
Capricor Company Contact:
AJ Bergmann, Chief Financial Officer abergmann@capricor.com
858.727.1755